- Login
- Register & Subscribe
- Language: EN FR DE
A team of researchers in the US has reported that the CD95 receptor promotes tumour growth, a finding that advances work done at the German Cancer Research Center in Heidelberg, and at its spin-out, Apogenix GmbH.
Germany
Sanofi-Aventis SA said that it has entered into a research alliance with the Massachusetts Institute of Technology’s Center for Biomedical Innovation that will support the translation of basic research into new healthcare products.
France
The US National Institute of Allergy and Infectious Diseases has awarded a grant to a San Diego, California-based company to progress new technology for fighting S. aureus by disrupting a signalling process called quorum sensing.
United States
Scientists at the J. Craig Venter Institute in the US have reported the successful construction of a self-replicating, synthetic bacterial cell, technology that could have future application to pharmaceuticals.
United States
The US National Institutes of Health have awarded $3.4 million to GlycoVaxyn AG of Switzerland and a researcher at the Harvard Medical School to carry out preclinical work on a new S. aureus vaccine for hospital-acquired infections.
Switzerland
Two US centres of the Fraunhofer-Gesellschaft in Germany, together with Boston University and the biopharmaceutical company iBio, Inc, have launched a factory that uses non-genetically modified green plants to produce vaccines.
United States
Scientists in the UK have identified a gene that appears to enable tumour cells to survive radiotherapy. Suppression of the gene could therefore make current radiotherapies more effective, according to the charity, Cancer Research UK.
United Kingdom
AstraZeneca Plc has concluded a collaborative research agreement with the University of Pennsylvania in the US to generate new drug candidates for Alzheimer’s disease. Financial details were not disclosed.
United Kingdom
Cancer Research Technology (CRT), the technology transfer arm of the charity, Cancer Research UK, has reached an agreement with Cephalon Inc of the US to develop new small molecule drugs targeting members of the protein kinase C family.
United Kingdom
Pfizer Inc has reached an agreement with King’s College London to site a small team of its scientists at the Wolfson Centre for Age-Related Disease at the King’s Guys campus in London to conduct basic research into the biology of pain.
United States
Tuesday September 7 2010
Friday September 3 2010
Friday August 20 2010
Friday August 20 2010
Thursday August 19 2010